Entity Details

Primary name 5NTC_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP49902
EntryName5NTC_HUMAN
FullNameCytosolic purine 5'-nucleotidase
TaxID9606
Evidenceevidence at protein level
Length561
SequenceStatuscomplete
DateCreated1996-10-01
DateModified2021-06-02

Ontological Relatives

GenesNT5C2

GO terms

Show/Hide Table
GOName
GO:0000166 nucleotide binding
GO:0005829 cytosol
GO:0006195 purine nucleotide catabolic process
GO:0008253 5'-nucleotidase activity
GO:0017144 drug metabolic process
GO:0046040 IMP metabolic process
GO:0046085 adenosine metabolic process
GO:0046872 metal ion binding
GO:0050484 GMP 5'-nucleotidase activity

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm

Domains

Show/Hide Table
DomainNameCategoryType
IPR008380 HAD-superfamily hydrolase, subfamily IG, 5'-nucleotidaseFamilyFamily
IPR016695 Purine 5'-nucleotidaseFamilyFamily
IPR023214 HAD superfamilyFamilyHomologous superfamily
IPR036412 HAD-like superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
613162 OMIMSpastic paraplegia 45, autosomal recessive (SPG45)A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG45 patients manifest mental retardation, contractures and learning disability. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00171 ATPDrugbanksmall molecule
DB00811 RibavirinDrugbanksmall molecule
DB06408 TaribavirinDrugbanksmall molecule